Role of pleural transthoracic ultrasound guidance
Sir, We read with interest the article by Ferreiro et al., [1] recently published in your journal, focused on the correct management of pleural malignant effusions.
We absolutely agree that thoracentesis is one of the first approaches in pleural malignant effusions. However, procedure-related complications with transthoracic ultrasound (TUS) guidance are less frequent than reported in the review. We have performed 3870 drainages in the last 10 year with TUS guidance. [2] A diagnosis of malignant effusion was done in 630 patients (18%) with cytology on fluid samples. The rate of major complications was low: only four patients (0.1%) had iatrogenic pneumothorax (three showed partial pneumothorax and one subtotal pneumothorax; with full lung reexpansion in each case), and two patients had reexpansion lung edema. [2] Under TUS guidance, it is also possible to determine the real-time characteristics of pleural effusion. [3] Indeed, accordingly to the US pattern of pleural effusion (anechoic, complex nonloculated, complex loculated, and homogeneously hyperechoic) [ Figure 1 ], it is possible to choose the right needle size, i.e., generally an atraumatic 20-gauge and to use a low-flow and low-pressure Letters to the Editor aspiration system. [3] Moreover, it is advisable the use of dedicated probe, i.e., with a central hole through which the needle set is introduced. [4] One of the most relevant advantages of US guidance is the real-time needle visualization during the procedure. [4] In this way, the physician can retract the needle during lung reexpansion, avoiding pneumothorax, and hemothorax [ Figure 2 ].
TUS guidance is the primary procedure in the pleural fine needle aspiration biopsy (FNAB). [5] It allows us to perform a step-by-step FNAB with more ease and advantages in comparison with blind or computed tomography scan-guided biopsies. [5] Moreover, the FNAB-dedicated probes allow the physician to reach the lesion under the coaxial view, getting specimens of length, thickness, and quality adequate for pathology assessment. [5] Financial support and sponsorship Nil.
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Prevalence of antibodies against the Middle East Respiratory Syndrome coronavirus, influenza A and B viruses among blood donors, Saudi Arabia
Sir, Convalescent plasma therapy has been proposed as a therapy for the Middle East Respiratory Syndrome coronavirus (MERS-CoV) and for influenza A and B viruses. [1] [2] [3] As part of a protocol for collecting convalescent plasma, we have reported low seroprevalence of MERS-CoV antibodies among cohorts of patients with suspected or laboratory-confirmed MERS-CoV infection, health-care workers, and household contacts exposed to MERS-CoV.
[4] Subsequently, we further screened healthy Saudi male blood donors as a potential source for convalescent plasma. We tested 170 consecutive donors aged 18-32 years in the 1 st week of October 2016 for anti-MERS antibodies and 100 consecutive donors for influenza A and B antibodies. The influenza virus A IgG enzyme-linked immunosorbent assay (ELISA) and influenza virus B IgG ELISA were used for qualitative antibody testing according to manufacturer's instructions (NovaTec Immundiagnostica, Dietzenbach, Germany). Briefly, serum samples were diluted 1 in 100 and incubated with ELISA wells coated with influenza A virus antigen (prepared from the strain A/Texas/1/77 [H3N2]) and the influenza B virus antigen (prepared from the strain B/Hong Kong/5/72). Binding of serum IgG to influenza antigens was detected by the addition of horseradish peroxidase-labeled antihuman IgG conjugate followed by the incubation with the substrate (tetramethylbenzidine). Intensity of the developed color (at 450 nm) was measured, which was proportional to specific IgG titers. The ELISAs also offered semi-quantitative evaluation of the results using the arbitrary units "NovaTec-Units" (NTU). The NTUs were calculated with the following formula: Subject's mean absorbance ×10/cutoff = NTU. NTU >11 was considered positive and <9 was considered negative otherwise borderline. IgG MERS-CoV antibodies were tested by ELISA according to manufacturer's instructions (Euroimmun AG, Lübeck, Germany). Results were reported as optic density (OD) ratio, which is calculated as the OD value of the patient's sample divided by the calibrator OD value. Cutoff values recommended by the manufacturer are a ratio of <0.8 is negative, >0.8 and <1.1 is borderline, and a ratio of >1.1 is positive. Most of our cohort (64%) tested positive for IgG Influenza A whereas 35% of them were positive for influenza B antibodies [ Table 1 ]. The titers of anti-influenza A were higher than that of 
